Avalyn Pharma COO Melissa Rhodes sells 13,300 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avalyn Pharma Inc. Chief Operating Officer Melissa Rhodes exercised options for 13,300 common shares at an exercise price of $4.62 per share on November 17, 2026, then sold 13,300 shares under a Rule 10b5-1 trading plan adopted July 30, 2026. The reported weighted-average sale prices were $27.7918 per share for 10,875 shares, $28.2069 per share for 2,025 shares, and $29.2286 per share for 400 shares. Her reported option position after exercise was 170,638 shares.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 13,300 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 13,300 | $4.62 | $61K |
| Sale | Common Stock F1, F2 | 10,875 | $27.7918 | $302K |
| Sale | Common Stock F1, F3 | 2,025 | $28.2069 | $57K |
| Sale | Common Stock F1, F4 | 400 | $29.2286 | $12K |
Footnotes (5)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.10 to $28.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.10 to $28.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.11 to $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F5. 25% of the shares underlying this option vested and became exercisable on September 11, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
exercise price financial
substantially equal monthly installments technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AVLN options did Melissa Rhodes exercise, and at what price?
What was the vesting schedule for Melissa Rhodes's AVLN option?
AI-generated analysis. How Rhea-AI works. Not financial advice.